FIG. 4 shows the infra red (FT/IR) spectrum of ABT-888 Crystalline Form 1.

FIG. 5 shows the Raman spectrum of ABT-888 Crystalline Form 1.

FIG. 6 shows a theoretical PXRD spectrum of ABT-888 Crystalline Form 2.

FIG. 7 shows an experimental PXRD spectrum of ABT-888 Crystalline Form 2.

FIG. 8 shows the infra red (FT/IR) spectrum of ABT-888 Crystalline Form 2.

FIG. 9 shows the Raman spectrum of ABT-888 Crystalline Form 2.

SUMMARY OF THE INVENTION

In an aspect, there is provided 2-((R)-2-Methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide Crystalline Form 1 which, when measured at -100°C ± 2°C in the tetragonal crystal system and $P4_32_12$ space group with radiation at 0.7107 Å, is characterized by respective lattice parameter values a, b and c of 8.218 Å ± 0.002Å, 8.218 Å± 0.002 Å and 36.06 Å ± 0.01 Å and α, β and γ values of 90°, and wherein when measured at 25°C ± 2°C with radiation at 1.54178 Å, is characterized by a powder diffraction pattern having 2θ values of 9.9°, 11.0° and 11.8° ±0.1° and one or more than one additional peaks having respective 2θ values of 14.6°, 15.2°, 18.2°, 19.6°, 20.3°, 21.3°, 22.5°, 22.8°, 24.7°, 28.5° and 29.1° ±0.1°.

One embodiment of this invention pertains to 2-((R)-2-Methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide Crystalline Form 1 which, when measured at about -100°C in the tetragonal crystal system and $P4_32_12$ space group with radiation at 0.7107 Å, is characterized by respective lattice parameter values a, b and c of 8.218 Å ± 0.002Å, 8.218 Å ± 0.002 Å and 36.06 Å ± 0.01 Å and α, β and γ values of 90°.

Another embodiment pertains to 2-((R)-2-Methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide Crystalline Form 1 which, when measured at about 25°C with radiation at 1.54178 Å, is characterized by a powder diffraction pattern having respective 2θ values of about 9.9°, 11.0° and 11.8° and one or more than one additional peaks having respective 2θ values of about 14.6°, 15.2°, 18.2°, 19.6°, 20.3°, 21.3°, 22.5°, 22.8°, 24.7°, 28.5° and 29.1°.

Still another embodiment pertains to compositions comprising an excipient and 2-((R)-2-Methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide Crystalline Form 1 which, when measured at about -100°C in the tetragonal crystal system and $P4_32_12$ space group with radiation at 0.7107 Å, is characterized by respective lattice parameter values a, b and c of 8.218 Å ± 0.002Å, 8.218 Å ± 0.002 Å and 36.06 Å ± 0.01 Å and α, β and γ values of 90°.

WE CLAIM:

1. 2-((R)-2-Methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide Crystalline Form 1 which, when measured at -100°C ± 2°C in the tetragonal crystal system and $P4_32_12$ space group with radiation at 0.7107 Å, is characterized by respective lattice parameter values a, b and c of 8.218 Å ± 0.002Å, 8.218 Å± 0.002 Å and 36.06 Å ± 0.01 Å ~~36.06 Å ±~~ and α, β and γ values of 90°, and wherein when measured at 25°C ± 2°C with radiation at 1.54178 Å, is characterized by a powder diffraction pattern having 2θ values of 9.9°, 11.0° and 11.8° ±0.1° ~~11.8° ±0.1°~~ and one or more than one additional peaks having respective 2θ values of 14.6°, 15.2°, 18.2°, 19.6°, 20.3°, 21.3°, 22.5°, 22.8°, 24.7°, 28.5° and 29.1° ±0.1° ~~29.1° ±0.1°~~.